Lineage Cell Therapeutics (LCTX) Depreciation and Depletion (2010 - 2016)

Lineage Cell Therapeutics' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $248000.0 for Q3 2016.

• On a quarterly basis, Depreciation and Depletion fell 6.06% year-over-year to $248000.0 in Q3 2016; TTM through Sep 2016 was $1.3 million, a 25.65% increase from a year earlier, with the FY2015 full-year figure at $1.1 million, up 2.57% from the prior year.
• Depreciation and Depletion fell to $248000.0 in Q3 2016 per LCTX's latest filing, from $319000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $429000.0 in Q1 2016 and bottomed at $88692.0 in Q1 2012.
• The 5-year median for Depreciation and Depletion is $249000.0 (2015), against an average of $217650.4.
• Across the five-year window, Depreciation and Depletion retreated 24.75% in 2012 and soared 134.71% in 2014, its largest moves.
• Year by year, Depreciation and Depletion stood at $102820.0 in 2012, then surged by 130.86% to $237370.0 in 2013, then advanced by 8.27% to $257000.0 in 2014, then gained by 17.51% to $302000.0 in 2015, then fell by 17.88% to $248000.0 in 2016.
• Per Business Quant, the three latest LCTX Depreciation and Depletion figures stand at $248000.0 (Q3 2016), $319000.0 (Q2 2016), and $429000.0 (Q1 2016).